Diarrheal illnesses continue to pose a significant health threat to young children in many regions worldwide. While those in developed countries often recover quickly due to access to clean water and medical treatment, severe diarrhea can be life-threatening in low- and middle-income nations. It can lead to dangerous dehydration, inadequate nutrition, slowed growth, and even death. A primary culprit is a bacterium known as enterotoxigenic Escherichia coli, or ETEC.
For decades, scientists have been working to create a vaccine, but progress has been slow and challenging. Recently, researchers from the University of Bergen and NORCE achieved a notable milestone. Their vaccine technology has been licensed to the global vaccine manufacturer Valneva, which will continue developing it into a potential future vaccine. This achievement results from years of international research and collaboration involving institutions like the University of Bergen, NORCE, Institut Pasteur, the Indian Institute of Science, Tulane University, and South Dakota State University. The project is supported by VIS, an organization that manages innovation and technology transfer for Norwegian research institutions.
The aim is to develop a vaccine against ETEC, which is among the most common bacterial causes of severe diarrhea worldwide. Millions of infections occur annually, especially among children in impoverished countries and travelers to these areas. Young children are particularly at risk because repeated infections can negatively impact nutrition, growth, cognitive development, and overall health.
This research originates from a program that started in the 1980s, with the specific technology behind the current licensing being developed since 2009. Instead of relying on a single breakthrough, scientists addressed numerous small scientific challenges along the way. Their main focus was on a harmful toxin called STh, one of the primary substances ETEC uses to cause illness. Targeting this toxin has been difficult because it is tiny and hard for the immune system to detect safely.
Through careful redesigning and a better understanding gained over many years, the researchers developed an encouraging vaccine platform now ready for industrial-scale development. Under the licensing agreement, Valneva holds exclusive rights to further develop the vaccine. Importantly, the agreement also envisions potential plans to make the vaccine accessible through public health programs in low- and middle-income countries if further development proves successful, ensuring that those most in need can benefit.
Despite the promising progress, several critical steps remain before the vaccine can be widely distributed. It must undergo laboratory testing, human clinical trials to assess safety and efficacy, and receive regulatory approval—processes that typically take many years.
This news highlights a significant advancement from academic research toward a real-world solution, a testament to decades of scientific effort and global collaboration. However, rigorous testing in clinical trials is essential to confirm that the vaccine is safe and effective. If these trials are successful, this technology could play a major role in reducing childhood diarrhea worldwide.
For those interested in health and wellness, there are ongoing studies about how ultra-processed foods and red meat impact longevity and why seafood might support healthy aging. Additional recent research covers topics like the benefits of pickle juice and how time-restricted eating can be a simple strategy to combat aging and cancer.
Source: University of Bergen.
